These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 29874282)

  • 21. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.
    Wehling C; Amon O; Bommer M; Hoppe B; Kentouche K; Schalk G; Weimer R; Wiesener M; Hohenstein B; Tönshoff B; Büscher R; Fehrenbach H; Gök ÖN; Kirschfink M
    Clin Exp Immunol; 2017 Feb; 187(2):304-315. PubMed ID: 27784126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.
    Servais A; Noël LH; Roumenina LT; Le Quintrec M; Ngo S; Dragon-Durey MA; Macher MA; Zuber J; Karras A; Provot F; Moulin B; Grünfeld JP; Niaudet P; Lesavre P; Frémeaux-Bacchi V
    Kidney Int; 2012 Aug; 82(4):454-64. PubMed ID: 22456601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The role of complement in physiology and pathology].
    Klaska I; Nowak JZ
    Postepy Hig Med Dosw (Online); 2007; 61():167-77. PubMed ID: 17410057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
    Michels MAHM; van de Kar NCAJ; van Kraaij SAW; Sarlea SA; Gracchi V; Engels FAPT; Dorresteijn EM; van der Deure J; Duineveld C; Wetzels JFM; van den Heuvel LPWJ; Volokhina EB
    Front Immunol; 2021; 12():715704. PubMed ID: 34456924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells.
    Sartain SE; Turner NA; Moake JL
    J Biol Chem; 2018 May; 293(19):7195-7208. PubMed ID: 29555686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Benefits of Complement Measurements for the Clinical Practice.
    Grunenwald A; Roumenina LT
    Methods Mol Biol; 2021; 2227():1-20. PubMed ID: 33847926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complement and glomerular disease: new insights.
    Pickering M; Cook HT
    Curr Opin Nephrol Hypertens; 2011 May; 20(3):271-7. PubMed ID: 21422921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Longitudinal associations of the alternative and terminal pathways of complement activation with adiposity: The CODAM study.
    Xin Y; Hertle E; van der Kallen CJH; Schalkwijk CG; Stehouwer CDA; van Greevenbroek MMJ
    Obes Res Clin Pract; 2018; 12(3):286-292. PubMed ID: 29174517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.
    Williams AL; Gullipalli D; Ueda Y; Sato S; Zhou L; Miwa T; Tung KS; Song WC
    Kidney Int; 2017 Jun; 91(6):1386-1397. PubMed ID: 28139294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition.
    Riedemann NC; Habel M; Ziereisen J; Hermann M; Schneider C; Wehling C; Kirschfink M; Kentouche K; Guo R
    Clin Immunol; 2017 Jul; 180():25-32. PubMed ID: 28366510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy.
    Togarsimalemath SK; Sethi SK; Duggal R; Le Quintrec M; Jha P; Daniel R; Gonnet F; Bansal S; Roumenina LT; Fremeaux-Bacchi V; Kher V; Dragon-Durey MA
    Kidney Int; 2017 Oct; 92(4):876-887. PubMed ID: 28729035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional Hemolytic Test for Complement Alternative Pathway Convertase Activity.
    Michels MAHM; van de Kar NCAJ; Volokhina EB; van den Heuvel BLPWJ
    Methods Mol Biol; 2021; 2227():83-96. PubMed ID: 33847933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis.
    Turner NA; Moake J
    PLoS One; 2013; 8(3):e59372. PubMed ID: 23555663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diseases of complement dysregulation-an overview.
    Wong EKS; Kavanagh D
    Semin Immunopathol; 2018 Jan; 40(1):49-64. PubMed ID: 29327071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy?
    Michels MAHM; Volokhina EB; van de Kar NCAJ; van den Heuvel LPWJ
    Pediatr Nephrol; 2019 Aug; 34(8):1349-1367. PubMed ID: 30141176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice.
    Sekine H; Kinser TT; Qiao F; Martinez E; Paulling E; Ruiz P; Gilkeson GS; Tomlinson S
    Arthritis Rheum; 2011 Apr; 63(4):1076-85. PubMed ID: 21452327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway.
    Anliker-Ort M; Dingemanse J; van den Anker J; Kaufmann P
    Front Immunol; 2020; 11():599417. PubMed ID: 33362783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation.
    Ueda Y; Miwa T; Ito D; Kim H; Sato S; Gullipalli D; Zhou L; Golla M; Song D; Dunaief JL; Palmer MB; Song WC
    Kidney Int; 2019 Jul; 96(1):67-79. PubMed ID: 30910380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complement Dysregulation and Disease: Insights from Contemporary Genetics.
    Liszewski MK; Java A; Schramm EC; Atkinson JP
    Annu Rev Pathol; 2017 Jan; 12():25-52. PubMed ID: 27959629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses.
    Nilsson PH; Thomas AM; Bergseth G; Gustavsen A; Volokhina EB; van den Heuvel LP; Barratt-Due A; Mollnes TE
    Mol Immunol; 2017 Sep; 89():111-114. PubMed ID: 28610663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.